Evolution of Hypertrophic Cardiomyopathy to a Contemporary Treatable Disease
Population
2 patients with hypertrophic cardiomyopathy and a strong family history of sudden cardiac death.
Design
Case_series
Follow-up
Up to 21 years
Authors
Discussion
Loading...
Member takes
Implication
Supports individualized ICD and myectomy decisions in HCM; leaves open generalizability pending prospective data.
Key Points
- This paper explores the evolution of hypertrophic cardiomyopathy (HCM) and its treatability through advanced interventions.
- Presented cases of two patients with nonobstructive and obstructive HCM respectively.
- Both patients received implantable cardioverter-defibrillators (ICDs) for primary prevention and underwent surgical interventions as needed.
- Patient progress was evaluated over multiple years, monitoring for episodes of ventricular fibrillation and heart failure symptoms.
- Patient 1, with nonobstructive HCM, remained asymptomatic after ICD interventions following two episodes of ventricular fibrillation.
- Patient 2, with obstructive HCM, experienced symptomatic improvement after surgical septal myectomy, abolishing heart failure symptoms.
- Both patients show positive long-term outcomes with effective management strategies for HCM.
Structured PICO
P
Population
2 patients with hypertrophic cardiomyopathy (1 nonobstructive, 1 obstructive) and a strong family history of sudden cardiac death.
I
Intervention
Implantable cardioverter-defibrillator (ICD) for primary prevention in both patients, and surgical septal myectomy in the patient with obstructive HCM.
O
Outcome
Prevention of sudden cardiac death and relief of heart failure symptoms.hard clinical
These cases illustrate that hypertrophic cardiomyopathy is a treatable disease where sudden death can be prevented with ICDs and heart failure symptoms effectively managed with septal reduction therapy.
Cite This Study
Maron et al. (2012) studied this question.